IDEXX Laboratories Inc (IDXX)vsVeracyte Inc (VCYT)
IDXX
IDEXX Laboratories Inc
$575.72
+0.97%
HEALTHCARE · Cap: $45.53B
VCYT
Veracyte Inc
$32.79
-0.46%
HEALTHCARE · Cap: $2.62B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 732% more annual revenue ($4.30B vs $517.14M). IDXX leads profitability with a 24.6% profit margin vs 12.8%. VCYT trades at a lower P/E of 41.2x. IDXX earns a higher WallStSmart Score of 61/100 (C+).
IDXX
Buy61
out of 100
Grade: C+
VCYT
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.2%
Fair Value
$462.85
Current Price
$575.72
$112.87 premium
Margin of Safety
+3.9%
Fair Value
$37.44
Current Price
$32.79
$4.65 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 66 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.8%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
18.5% revenue growth
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
ROE of 5.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : VCYT
The strongest argument for VCYT centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 18.5% demonstrates continued momentum.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.
Bear Case : VCYT
The primary concerns for VCYT are Return on Equity, P/E Ratio. A P/E of 41.2x leaves little room for execution misses.
Key Dynamics to Monitor
IDXX profiles as a mature stock while VCYT is a growth play — different risk/reward profiles.
VCYT carries more volatility with a beta of 1.96 — expect wider price swings.
VCYT is growing revenue faster at 18.5% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (61/100 vs 59/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Veracyte Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?